Celis H, Yodfat Y, Thijs L, Clement D, Cozic J, De Cort P, Forette F, Grégoire M, Heyrman J, Stibbe G, Van den Haute M, Staessen J, Fagard R
Klinisch Laboratorium Hypertensie, Inwendige Geneeskunde-Cardiologie, Leuven, Belgium.
Fam Pract. 1996 Apr;13(2):138-43.
This interim report from the Syst-Eur trial investigated the level of blood pressure control achieved during the double-blind period in patients followed in general practices.
In the Syst-Eur trial elderly patients (60 years or older) with isolated systolic hypertension were randomized to either active or placebo treatment. Active treatment consisted of nitrendipine combined with enalapril and/or hydrochlorothiazide to reduce systolic pressure to < 150 mmHg and by > or = 20 mmHg. Matching placebos were used in the control group.
This analysis was restricted to patients of general practitioners who had been followed for at least 12 months. The placebo (N = 204) and active treatment (N = 217) groups had similar characteristics at randomization. At one year, the difference in sitting pressure between the two treatment groups was 10 mmHg systolic and 4 mmHg diastolic. Fewer patients remained on monotherapy in the placebo than in the active treatment group and on placebo the second and third line medications were started earlier. Nitrendipine tablets were discontinued in 10 patients on placebo and in 21 patients assigned to active treatment (P < 0.001 for all comparisons).
A significant blood pressure reduction can be achieved and maintained in older patients with isolated systolic hypertension followed by general practitioners. Whether this blood pressure reduction results in a clinically meaningful decrease of cardiovascular complications is under investigation.
本项来自 Syst-Eur 试验的中期报告,调查了在全科医疗中接受随访的患者在双盲期所达到的血压控制水平。
在 Syst-Eur 试验中,将 60 岁及以上的单纯收缩期高血压老年患者随机分为活性治疗组或安慰剂治疗组。活性治疗包括使用尼群地平联合依那普利和/或氢氯噻嗪,将收缩压降至<150 mmHg 且降低幅度≥20 mmHg。对照组使用匹配的安慰剂。
本分析仅限于随访至少 12 个月的全科医生的患者。安慰剂组(N = 204)和活性治疗组(N = 217)在随机分组时具有相似的特征。一年时,两个治疗组坐位血压的差异为收缩压 10 mmHg,舒张压 4 mmHg。与活性治疗组相比,安慰剂组中接受单一疗法的患者更少,且在安慰剂组中二线和三线药物更早开始使用。安慰剂组有 10 例患者停用尼群地平片,活性治疗组有 21 例患者停用(所有比较 P < 0.001)。
在全科医生随访的老年单纯收缩期高血压患者中,可以实现并维持显著的血压降低。这种血压降低是否会导致心血管并发症在临床上有意义的减少正在研究中。